CU23612A1 - Combinaciones terapéuticas para potenciar el efecto de la terapia con anticuerpos contra el receptor del factor de crecimiento epidérmico - Google Patents

Combinaciones terapéuticas para potenciar el efecto de la terapia con anticuerpos contra el receptor del factor de crecimiento epidérmico

Info

Publication number
CU23612A1
CU23612A1 CU20060190A CU20060190A CU23612A1 CU 23612 A1 CU23612 A1 CU 23612A1 CU 20060190 A CU20060190 A CU 20060190A CU 20060190 A CU20060190 A CU 20060190A CU 23612 A1 CU23612 A1 CU 23612A1
Authority
CU
Cuba
Prior art keywords
growth factor
epidermal growth
therapy
enhance
receiver
Prior art date
Application number
CU20060190A
Other languages
English (en)
Inventor
Gomez Audry Fernandez
Hidalgo Greta Garrido
Delgado Irene Beausoleil
Requena Alejandro Lopez
Ramirez Belinda Sanchez
Molina Luis Enrique Fernandez
Rodriguez Rolando Perez
Original Assignee
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40223744&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU23612(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular
Priority to CU20060190A priority Critical patent/CU23612A1/es
Priority to ARP070104260A priority patent/AR063011A1/es
Priority to MX2009003159A priority patent/MX2009003159A/es
Priority to PCT/CU2007/000017 priority patent/WO2008037225A1/es
Priority to CN2012104701143A priority patent/CN102940883A/zh
Priority to EP07817381.2A priority patent/EP2070547B1/en
Priority to BRPI0717142-0A priority patent/BRPI0717142A2/pt
Priority to CL200702797A priority patent/CL2007002797A1/es
Priority to CA2664795A priority patent/CA2664795C/en
Priority to AU2007302429A priority patent/AU2007302429B2/en
Priority to PE2007001310A priority patent/PE20080674A1/es
Priority to KR1020097007699A priority patent/KR101482957B1/ko
Priority to TR2009/02344T priority patent/TR200902344T1/xx
Priority to CN200780036290A priority patent/CN101678099A/zh
Priority to US12/442,608 priority patent/US20100047207A1/en
Priority to UY30616A priority patent/UY30616A1/es
Priority to CO09030399A priority patent/CO6160338A2/es
Priority to TN2009000104A priority patent/TN2009000104A1/fr
Priority to MA31815A priority patent/MA30811B1/fr
Priority to CR10753A priority patent/CR10753A/es
Publication of CU23612A1 publication Critical patent/CU23612A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención está relacionada con el campo de la biotecnología y describe combinaciones terapéuticas específicas, que aumentan la eficacia de la terapia con anticuerpos monoclonales (AcMs) contra el receptor del Factor de Crecimiento Epidérmico (EGFR, del inglés ¨epidermal growth factor receptor¨) e interferones (INFs) de tipo I (alfa/beta).
CU20060190A 2006-09-29 2006-09-29 Combinaciones terapéuticas para potenciar el efecto de la terapia con anticuerpos contra el receptor del factor de crecimiento epidérmico CU23612A1 (es)

Priority Applications (20)

Application Number Priority Date Filing Date Title
CU20060190A CU23612A1 (es) 2006-09-29 2006-09-29 Combinaciones terapéuticas para potenciar el efecto de la terapia con anticuerpos contra el receptor del factor de crecimiento epidérmico
ARP070104260A AR063011A1 (es) 2006-09-29 2007-09-26 Composiciones terapeuticas para potenciar el efecto de la terapia con anticuerpos contra el receptor del factor de crecimiento epidermico
US12/442,608 US20100047207A1 (en) 2006-09-29 2007-09-27 Therapeutic Composition To Improve The Effect Of The Therapy With Anti-Epidermal Growth Factor Receptor Antibodies
CA2664795A CA2664795C (en) 2006-09-29 2007-09-27 Therapeutic compositions to improve the effect of the therapy with anti-epidermal growth factor receptor antibodies
KR1020097007699A KR101482957B1 (ko) 2006-09-29 2007-09-27 상피 성장 인자 수용체 항체에 대항하는 항체 치료의 효과를 개선하기 위한 치료 조성물
CN2012104701143A CN102940883A (zh) 2006-09-29 2007-09-27 用于加强使用针对表皮生长因子受体的抗体的疗法的效果的治疗组合物
EP07817381.2A EP2070547B1 (en) 2006-09-29 2007-09-27 A composition comprising humanized anti-egfr mab h-r3 antibody and type i inf for use in treating cancer
BRPI0717142-0A BRPI0717142A2 (pt) 2006-09-29 2007-09-27 Composição terapêutica e kit de reativos para uso terapêutico
CL200702797A CL2007002797A1 (es) 2006-09-29 2007-09-27 Composicion terapeutica que comprende un anticuerpo contra el receptor del egf, interferon y excipientes adecuados para su administracion por via intravenosa.
MX2009003159A MX2009003159A (es) 2006-09-29 2007-09-27 Composiciones terapeuticas para potenciar el efecto de la terapia con anticuerpos contra el receptor del factor de crecimiento epidermico.
AU2007302429A AU2007302429B2 (en) 2006-09-29 2007-09-27 Therapeutic compositions for boosting the effect of antibody therapy against the epidermal growth factor receptor
PE2007001310A PE20080674A1 (es) 2006-09-29 2007-09-27 Composiciones terapeuticas para potenciar el efecto de la terapia con anticuerpos contra el receptor del factor de crecimiento epidermico
PCT/CU2007/000017 WO2008037225A1 (es) 2006-09-29 2007-09-27 Composiciones terapéuticas para potenciar el efecto de la terapia con anticuerpos contra el receptor del factor de crecimiento epidérmico
TR2009/02344T TR200902344T1 (tr) 2006-09-29 2007-09-27 Anti-epidermal büyüme faktörü reseptör antikorları ile terapinin etkisinin geliştirilmesi için terapötik bileşimler.
CN200780036290A CN101678099A (zh) 2006-09-29 2007-09-27 用于加强使用针对表皮生长因子受体的抗体的疗法的效果的治疗组合物
UY30616A UY30616A1 (es) 2006-09-29 2007-09-28 Composiciones terapéuticas para potenciar el efecto de la terapia con anticuerpos contra el receptor del factor de crecimiento epidérmico
CO09030399A CO6160338A2 (es) 2006-09-29 2009-03-25 Composiciones terapeuticas para potenciar el efecto de la terapia con anticuerpos contra el receptor del factor de crecimiento epidermico
TN2009000104A TN2009000104A1 (en) 2006-09-29 2009-03-27 Therapeutic compositions for boosting the effect of antibody therapy against the epidermal growth factor receptor
MA31815A MA30811B1 (fr) 2006-09-29 2009-04-23 Compositions therapeutiques permettant d'augmenter l'effet d'une therapie aux anticorps contre le recepteur du facteur de croissance epidermique
CR10753A CR10753A (es) 2006-09-29 2009-04-29 Composiciones terapeuticas para potenciar el efecto de la terapia con anticuerpos contra el receptor del factor de crecimiento epidermico

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20060190A CU23612A1 (es) 2006-09-29 2006-09-29 Combinaciones terapéuticas para potenciar el efecto de la terapia con anticuerpos contra el receptor del factor de crecimiento epidérmico

Publications (1)

Publication Number Publication Date
CU23612A1 true CU23612A1 (es) 2010-12-08

Family

ID=40223744

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20060190A CU23612A1 (es) 2006-09-29 2006-09-29 Combinaciones terapéuticas para potenciar el efecto de la terapia con anticuerpos contra el receptor del factor de crecimiento epidérmico

Country Status (19)

Country Link
US (1) US20100047207A1 (es)
EP (1) EP2070547B1 (es)
KR (1) KR101482957B1 (es)
CN (2) CN102940883A (es)
AR (1) AR063011A1 (es)
AU (1) AU2007302429B2 (es)
BR (1) BRPI0717142A2 (es)
CA (1) CA2664795C (es)
CL (1) CL2007002797A1 (es)
CO (1) CO6160338A2 (es)
CR (1) CR10753A (es)
CU (1) CU23612A1 (es)
MA (1) MA30811B1 (es)
MX (1) MX2009003159A (es)
PE (1) PE20080674A1 (es)
TN (1) TN2009000104A1 (es)
TR (1) TR200902344T1 (es)
UY (1) UY30616A1 (es)
WO (1) WO2008037225A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI500630B (zh) * 2008-06-20 2015-09-21 Centro Inmunologia Molecular 具有細胞生長抑制功效之表皮生長因子受體（ｅｇｆｒ）抑制劑類及彼等於腫瘤治療上之用途
CN103536917B (zh) * 2013-10-30 2015-03-11 苏州丁孚靶点生物技术有限公司 干扰素在治疗肿瘤中的用途及相关的产品和方法
US20180221478A1 (en) * 2015-07-27 2018-08-09 Innocimab Pte Ltd Treatment of patients diagnosed with pancreatic ductal adenocarcinoma using using monoclonal antibodies against the epidermal growth factor receptor (egfr)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
DE69324671D1 (de) * 1992-02-10 1999-06-02 Interferon Sciences Inc Verbesserte alpha-interferon-zusammensetzung und verfahren zu ihrer herstellung aus leukocyten des menschlichen peripheren blute
US20040127470A1 (en) * 1998-12-23 2004-07-01 Pharmacia Corporation Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist
US6949520B1 (en) * 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
PL363322A1 (en) * 2001-05-08 2004-11-15 Merck Patent Gmbh Combination therapy using anti-egfr antibodies and anti-hormonal agents
US20060134064A1 (en) * 2004-12-20 2006-06-22 David Goldstein Combined treatment with interferon-alpha and an epidermal growth factor receptor kinase inhibitor
US20110189178A1 (en) * 2010-02-04 2011-08-04 Xencor, Inc. Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions

Also Published As

Publication number Publication date
CA2664795A1 (en) 2008-04-03
PE20080674A1 (es) 2008-07-23
BRPI0717142A2 (pt) 2013-10-15
AU2007302429B2 (en) 2013-10-03
TN2009000104A1 (en) 2010-08-19
EP2070547A1 (en) 2009-06-17
CN101678099A (zh) 2010-03-24
CL2007002797A1 (es) 2008-04-18
UY30616A1 (es) 2008-05-02
AU2007302429A1 (en) 2008-04-03
US20100047207A1 (en) 2010-02-25
CR10753A (es) 2009-10-15
CO6160338A2 (es) 2010-05-20
AR063011A1 (es) 2008-12-23
MA30811B1 (fr) 2009-10-01
TR200902344T1 (tr) 2009-08-21
EP2070547A4 (en) 2011-11-02
KR20090058566A (ko) 2009-06-09
EP2070547B1 (en) 2013-04-24
MX2009003159A (es) 2009-04-06
CN102940883A (zh) 2013-02-27
CA2664795C (en) 2014-06-17
WO2008037225A1 (es) 2008-04-03
KR101482957B1 (ko) 2015-01-15

Similar Documents

Publication Publication Date Title
CR20110526A (es) Anticuerpos anti - tnf - alfa y sus usos
PE20210488A1 (es) Anticuerpos especificos para gucy2c y sus usos
UY30525A1 (es) Agentes de union dirigidos cuyo blanco es el pdgfr-alfa y sus usos
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
UY33407A (es) Anticuerpos específicos del factor gdf8 humano
CO2019005909A2 (es) Anticuerpos y polipéptidos dirigidos contra cd127
UY35399A (es) Conjugados de fármacos con anticuerpos
CL2017000864A1 (es) Composiciones y métodos de uso para tratar trastornos metabólicos
BR112013020500A2 (pt) anticorpo isolado, recombinante ou purificado
CR20140357A (es) Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
GT201400057A (es) 3-pirmidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante
GT201200058A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
GT201200125A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
CR20110631A (es) Inmunoglobulina con dominio variable dual y usos de la misma
CL2009001277A1 (es) Anticuerpo que enlaza especificamente el flt3 humano; fragmento de cualquiera de los anticuerpos antes dichos; acido polinucleico aislado; vector de expresion; celula recombinante; composicion farmaceutica y sus usos; producto que contiene el anticuerpo para tratar cancer
CR11837A (es) Inmunoglobulinas con dominio variable dual y usos de la misma
BR112012028764A2 (pt) anticor-pos antifgfr2
PE20140229A1 (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
AR074563A1 (es) Anticuerpos anti ligando 1 de muerte programada (anti-pd-l1) y su uso para mejorar la funcion de las celulas t
AR077867A1 (es) Terapia combinatoria de un anticuerpo cd20 afucosilado con fludarabina y/o mitoxantrona
CO2018001840A2 (es) Composiciones biofarmacéuticas que comprenden anticuerpos anti-il-5
CO2022002622A2 (es) Anticuerpos anti-cd73 y composiciones
CL2009000567A1 (es) Anticuerpo monoclonal que enlaza especificamente tyrp1 humano; fragmento de cualquiera de los anticuerpos antes indicado; acido nucleico que codifica en anticuerpo o fragmento; vector de expresion; celula recombinante; uso del anticuerpo o fragmento para tratar cancer.
CO7000770A2 (es) Terapia combinada para el tratamiento del cáncer de ovario
GT201300135A (es) Moduladores de gpr 119